In recent years, protein and polypeptide drugs have been favored by researchers because of their significant advantages in the treatment of diseases. On the other hand, the half-life of protein and polypeptide drugs is generally short, which affects the compliance of patients with medication. Combined with the pharmacokinetic characteristics of protein and peptide drugs, summarize the research progress of long-acting methods of protein and peptide drugs, mainly including amino acid substitution, site-directed modification mutation, fusion with other proteins by genetic means, glycosylation, cyclization, and polymer The methods of conjugation, stapling peptides, and the development of new dosage forms are hoped to be helpful to drug research and development workers.

Protein and polypeptide drugs have low toxicity, strong specificity, and good pharmacological activity against certain diseases. They are considered to be very promising biological macromolecules in drug development. Enzymatic degradation and rapid renal clearance result in a short half-life, which limits the use of the drug. Therefore, it is very important to carry out long-acting research on protein and polypeptide drugs. The strategy of prolonging their plasma half-life can not only improve the pharmacokinetic properties of established drugs, but also may develop new indications for drug use. Based on the pharmacokinetic characteristics of protein and peptide drugs, this paper reviews the research progress of long-acting technology of protein and peptide drugs.